According to the American Cancer Society, more than 40,000 patients are diagnosed with liver or biliary tract cancers each year, with cholangiocarcinomas accounting for around 8,000. Incidence has ...

Cholangiocarcinomas are malignant tumors that derive from cholangiocytes of small intrahepatic bile ducts or bile ductules (intrahepatic cholangiocarcinoma; ICC), or of large hilar or extrahepatic ...

Only a small number of bile duct cancers are intrahepatic. Intrahepatic bile duct cancers are also called intrahepatic cholangiocarcinomas. 2. Extrahepatic bile duct cancer: This type of cancer forms ...

Advanced non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the world. Epidermal growth factor receptor (EGFR) is expressed in 50% of NSCLCs, and its expression is ...

The Bismuth–Corlette classification system provides an anatomic description of the tumor location and longitudinal extension in the biliary tree (Figure 3). It is limited due to its failure to ...

Background: The addition of durvalumab or pembrolizumab to gemcitabine and cisplatin (GP) has been approved to statistically improve survival outcomes in patients with advanced biliary tract cancer.